Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1042/BCJ20220016

http://scihub22266oqcxt.onion/10.1042/BCJ20220016
suck pdf from google scholar
35195253!8883497!35195253
unlimited free pdf from europmc35195253    free
PDF from PMC    free
html from PMC    free
PDF vom PMID35195253  :  Publisher

suck abstract from ncbi

pmid35195253
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications #MMPMID35195253
  • Kell DB; Laubscher GJ; Pretorius E
  • Biochem J 2022[Feb]; 479 (4): 537-559 PMID35195253show ga
  • Post-acute sequelae of COVID (PASC), usually referred to as 'Long COVID' (a phenotype of COVID-19), is a relatively frequent consequence of SARS-CoV-2 infection, in which symptoms such as breathlessness, fatigue, 'brain fog', tissue damage, inflammation, and coagulopathies (dysfunctions of the blood coagulation system) persist long after the initial infection. It bears similarities to other post-viral syndromes, and to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Many regulatory health bodies still do not recognize this syndrome as a separate disease entity, and refer to it under the broad terminology of 'COVID', although its demographics are quite different from those of acute COVID-19. A few years ago, we discovered that fibrinogen in blood can clot into an anomalous 'amyloid' form of fibrin that (like other beta-rich amyloids and prions) is relatively resistant to proteolysis (fibrinolysis). The result, as is strongly manifested in platelet-poor plasma (PPP) of individuals with Long COVID, is extensive fibrin amyloid microclots that can persist, can entrap other proteins, and that may lead to the production of various autoantibodies. These microclots are more-or-less easily measured in PPP with the stain thioflavin T and a simple fluorescence microscope. Although the symptoms of Long COVID are multifarious, we here argue that the ability of these fibrin amyloid microclots (fibrinaloids) to block up capillaries, and thus to limit the passage of red blood cells and hence O2 exchange, can actually underpin the majority of these symptoms. Consistent with this, in a preliminary report, it has been shown that suitable and closely monitored 'triple' anticoagulant therapy that leads to the removal of the microclots also removes the other symptoms. Fibrin amyloid microclots represent a novel and potentially important target for both the understanding and treatment of Long COVID and related disorders.
  • |*Amyloid/blood/chemistry[MESH]
  • |*COVID-19/blood/drug therapy[MESH]
  • |*Lung/metabolism/virology[MESH]
  • |*Thrombosis/drug therapy/metabolism/virology[MESH]
  • |Anticoagulants/*therapeutic use[MESH]
  • |Fibrin/chemistry/metabolism[MESH]
  • |Humans[MESH]
  • |SARS-CoV-2/*metabolism[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    537 4.479 2022